Investigational drugs for the treatment of cervical cancer

Fabio Barra, Domenica Lorusso, Umberto Leone Roberti Maggiore, Antonino Ditto, Giorgio Bogani, Francesco Raspagliesi, Simone Ferrero

Research output: Contribution to journalReview article

Abstract

Introduction: Cervical cancer (CC) is currently the fourth most common malignant disease of women worldwide. Although the incidence and the mortality rates have been decreasing with screening detection and new treatment strategies, a significant number of metastatic or recurrent disease is still diagnosed. For those patients not amenable to curative treatments, such as surgery and radiation, palliative chemotherapy remains the standard of care. As chemotherapy regimens have limited activity, research is focalized on investigating novel pharmacologic strategies. Areas covered: This paper aims to give a complete and updated overview on investigated therapies for the treatment of CC. The authors review the results of clinical studies and highlight the ongoing trials. Expert opinion: Agents targeting various molecular pathways including epidermal growth factor receptor (EGFR), vascular endothelial growth factor (VEGF), mammalian target of rapamycin (mTOR), poly ADP-ribose polymerase (PARP), epigenetics and other biological mechanisms represent interesting investigational opportunities. Amongst such drugs, bevacizumab, an anti-VEGF monoclonal antibody, was the first targeted drug recently approved by the FDA for the treatment of patients with metastatic, recurrent, or persistent CC. Another interesting experimental approach is represented by immunotherapy, which is leading to promising results with to the development of therapeutic vaccines and immune checkpoints inhibitors.

Original languageEnglish
Pages (from-to)389-402
Number of pages14
JournalExpert Opinion on Investigational Drugs
Volume26
Issue number4
DOIs
Publication statusPublished - Apr 3 2017

Fingerprint

Investigational Drugs
Investigational Therapies
Uterine Cervical Neoplasms
Vascular Endothelial Growth Factor A
Therapeutics
Drug Therapy
Poly(ADP-ribose) Polymerases
Expert Testimony
Sirolimus
Standard of Care
Palliative Care
Epidermal Growth Factor Receptor
Epigenomics
Pharmaceutical Preparations
Immunotherapy
Vaccines
Monoclonal Antibodies
Radiation
Mortality
Incidence

Keywords

  • Angiogenesis inhibitors
  • cervical cancer
  • immunotherapy
  • investigational drugs
  • targeted therapy

ASJC Scopus subject areas

  • Pharmacology
  • Pharmacology (medical)

Cite this

Investigational drugs for the treatment of cervical cancer. / Barra, Fabio; Lorusso, Domenica; Leone Roberti Maggiore, Umberto; Ditto, Antonino; Bogani, Giorgio; Raspagliesi, Francesco; Ferrero, Simone.

In: Expert Opinion on Investigational Drugs, Vol. 26, No. 4, 03.04.2017, p. 389-402.

Research output: Contribution to journalReview article

@article{1c92633d128d4305b6f443e6b28453de,
title = "Investigational drugs for the treatment of cervical cancer",
abstract = "Introduction: Cervical cancer (CC) is currently the fourth most common malignant disease of women worldwide. Although the incidence and the mortality rates have been decreasing with screening detection and new treatment strategies, a significant number of metastatic or recurrent disease is still diagnosed. For those patients not amenable to curative treatments, such as surgery and radiation, palliative chemotherapy remains the standard of care. As chemotherapy regimens have limited activity, research is focalized on investigating novel pharmacologic strategies. Areas covered: This paper aims to give a complete and updated overview on investigated therapies for the treatment of CC. The authors review the results of clinical studies and highlight the ongoing trials. Expert opinion: Agents targeting various molecular pathways including epidermal growth factor receptor (EGFR), vascular endothelial growth factor (VEGF), mammalian target of rapamycin (mTOR), poly ADP-ribose polymerase (PARP), epigenetics and other biological mechanisms represent interesting investigational opportunities. Amongst such drugs, bevacizumab, an anti-VEGF monoclonal antibody, was the first targeted drug recently approved by the FDA for the treatment of patients with metastatic, recurrent, or persistent CC. Another interesting experimental approach is represented by immunotherapy, which is leading to promising results with to the development of therapeutic vaccines and immune checkpoints inhibitors.",
keywords = "Angiogenesis inhibitors, cervical cancer, immunotherapy, investigational drugs, targeted therapy",
author = "Fabio Barra and Domenica Lorusso and {Leone Roberti Maggiore}, Umberto and Antonino Ditto and Giorgio Bogani and Francesco Raspagliesi and Simone Ferrero",
year = "2017",
month = "4",
day = "3",
doi = "10.1080/13543784.2017.1302427",
language = "English",
volume = "26",
pages = "389--402",
journal = "Expert Opinion on Investigational Drugs",
issn = "1354-3784",
publisher = "Informa Healthcare",
number = "4",

}

TY - JOUR

T1 - Investigational drugs for the treatment of cervical cancer

AU - Barra, Fabio

AU - Lorusso, Domenica

AU - Leone Roberti Maggiore, Umberto

AU - Ditto, Antonino

AU - Bogani, Giorgio

AU - Raspagliesi, Francesco

AU - Ferrero, Simone

PY - 2017/4/3

Y1 - 2017/4/3

N2 - Introduction: Cervical cancer (CC) is currently the fourth most common malignant disease of women worldwide. Although the incidence and the mortality rates have been decreasing with screening detection and new treatment strategies, a significant number of metastatic or recurrent disease is still diagnosed. For those patients not amenable to curative treatments, such as surgery and radiation, palliative chemotherapy remains the standard of care. As chemotherapy regimens have limited activity, research is focalized on investigating novel pharmacologic strategies. Areas covered: This paper aims to give a complete and updated overview on investigated therapies for the treatment of CC. The authors review the results of clinical studies and highlight the ongoing trials. Expert opinion: Agents targeting various molecular pathways including epidermal growth factor receptor (EGFR), vascular endothelial growth factor (VEGF), mammalian target of rapamycin (mTOR), poly ADP-ribose polymerase (PARP), epigenetics and other biological mechanisms represent interesting investigational opportunities. Amongst such drugs, bevacizumab, an anti-VEGF monoclonal antibody, was the first targeted drug recently approved by the FDA for the treatment of patients with metastatic, recurrent, or persistent CC. Another interesting experimental approach is represented by immunotherapy, which is leading to promising results with to the development of therapeutic vaccines and immune checkpoints inhibitors.

AB - Introduction: Cervical cancer (CC) is currently the fourth most common malignant disease of women worldwide. Although the incidence and the mortality rates have been decreasing with screening detection and new treatment strategies, a significant number of metastatic or recurrent disease is still diagnosed. For those patients not amenable to curative treatments, such as surgery and radiation, palliative chemotherapy remains the standard of care. As chemotherapy regimens have limited activity, research is focalized on investigating novel pharmacologic strategies. Areas covered: This paper aims to give a complete and updated overview on investigated therapies for the treatment of CC. The authors review the results of clinical studies and highlight the ongoing trials. Expert opinion: Agents targeting various molecular pathways including epidermal growth factor receptor (EGFR), vascular endothelial growth factor (VEGF), mammalian target of rapamycin (mTOR), poly ADP-ribose polymerase (PARP), epigenetics and other biological mechanisms represent interesting investigational opportunities. Amongst such drugs, bevacizumab, an anti-VEGF monoclonal antibody, was the first targeted drug recently approved by the FDA for the treatment of patients with metastatic, recurrent, or persistent CC. Another interesting experimental approach is represented by immunotherapy, which is leading to promising results with to the development of therapeutic vaccines and immune checkpoints inhibitors.

KW - Angiogenesis inhibitors

KW - cervical cancer

KW - immunotherapy

KW - investigational drugs

KW - targeted therapy

UR - http://www.scopus.com/inward/record.url?scp=85016161882&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85016161882&partnerID=8YFLogxK

U2 - 10.1080/13543784.2017.1302427

DO - 10.1080/13543784.2017.1302427

M3 - Review article

AN - SCOPUS:85016161882

VL - 26

SP - 389

EP - 402

JO - Expert Opinion on Investigational Drugs

JF - Expert Opinion on Investigational Drugs

SN - 1354-3784

IS - 4

ER -